Perspectives: Psychedelics Potential As Therapy Undermined By Unregulated Use
Read recent commentaries about pharmaceutical issues.
The Washington Post:
Self-Medicating With Psychedelic Drugs Is A Dangerous Plan
The Food and Drug Administration is reviewing a series of studies involving psilocybin, the psychoactive component in “magic mushrooms,” and MDMA, also known as ecstasy, for treating severe depression and post-traumatic stress disorder (PTSD). Both ailments can be disabling and difficult to manage. (Leana S. Wen, 9/26)
Changes To Biosimilar Regulatory Framework Must Prioritize Patients
Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. (Leah Christl, 9/26)